12867844

Source:http://linkedlifedata.com/resource/pubmed/id/12867844

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0009429, umls-concept:C0238013, umls-concept:C0537894, umls-concept:C0556895, umls-concept:C1145701
pubmed:issue	7
pubmed:dateCreated	2003-7-17
pubmed:abstractText	Ina 24-month-old girl with acute lymphoblastic leukemia and invasive aspergillosis, only combination therapy with liposomal amphotericin B and caspofungin achieved a good response. Combination therapy could be a useful treatment option in children with invasive fungal disease, but before it can be routinely recommended, carefully controlled in vivo studies and well-designed randomized clinical trials are needed.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8701858
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Amphotericin B, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents, http://linkedlifedata.com/resource/pubmed/chemical/Echinocandins, http://linkedlifedata.com/resource/pubmed/chemical/Liposomes, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, Cyclic, http://linkedlifedata.com/resource/pubmed/chemical/caspofungin
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0891-3668
pubmed:author	pubmed-author:DupuisWolfgangW, pubmed-author:ElanjikalZijuZ, pubmed-author:JautzkeGünterG, pubmed-author:KlingebielThomasT, pubmed-author:LehrnbecherThomasT, pubmed-author:SörensenJanJ, pubmed-author:SchmidtHelgaH, pubmed-author:TintelnotKathrinK
pubmed:issnType	Print
pubmed:volume	22
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	653-6
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:12867844-Amphotericin B, pubmed-meshheading:12867844-Anti-Bacterial Agents, pubmed-meshheading:12867844-Aspergillosis, pubmed-meshheading:12867844-Dose-Response Relationship, Drug, pubmed-meshheading:12867844-Drug Administration Schedule, pubmed-meshheading:12867844-Drug Therapy, Combination, pubmed-meshheading:12867844-Echinocandins, pubmed-meshheading:12867844-Female, pubmed-meshheading:12867844-Follow-Up Studies, pubmed-meshheading:12867844-Fungemia, pubmed-meshheading:12867844-Humans, pubmed-meshheading:12867844-Infant, pubmed-meshheading:12867844-Liposomes, pubmed-meshheading:12867844-Opportunistic Infections, pubmed-meshheading:12867844-Peptides, pubmed-meshheading:12867844-Peptides, Cyclic, pubmed-meshheading:12867844-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:12867844-Risk Assessment, pubmed-meshheading:12867844-Severity of Illness Index, pubmed-meshheading:12867844-Tomography, X-Ray Computed, pubmed-meshheading:12867844-Treatment Outcome
pubmed:year	2003
pubmed:articleTitle	Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis.
pubmed:affiliation	Department of Pediatric Hematology, Children's Hospital III, Frankfurt, Germany.
pubmed:publicationType	Journal Article, Case Reports